Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Short-term Investments (2020 - 2025)

Historic Short-term Investments for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Q3 2025 value amounting to $289.1 million.

  • Tarsus Pharmaceuticals' Short-term Investments rose 10542.06% to $289.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $289.1 million, marking a year-over-year increase of 10542.06%. This contributed to the annual value of $196.6 million for FY2024, which is 777803.61% up from last year.
  • Latest data reveals that Tarsus Pharmaceuticals reported Short-term Investments of $289.1 million as of Q3 2025, which was up 10542.06% from $284.5 million recorded in Q2 2025.
  • Tarsus Pharmaceuticals' 5-year Short-term Investments high stood at $289.1 million for Q3 2025, and its period low was $20000.0 during Q1 2021.
  • Its 5-year average for Short-term Investments is $113.9 million, with a median of $120.0 million in 2023.
  • Examining YoY changes over the last 5 years, Tarsus Pharmaceuticals' Short-term Investments showed a top increase of 4636804.12% in 2023 and a maximum decrease of 9828.36% in 2023.
  • Tarsus Pharmaceuticals' Short-term Investments (Quarter) stood at $483000.0 in 2021, then soared by 29996.48% to $145.4 million in 2022, then crashed by 98.28% to $2.5 million in 2023, then surged by 7778.04% to $196.6 million in 2024, then skyrocketed by 47.09% to $289.1 million in 2025.
  • Its Short-term Investments stands at $289.1 million for Q3 2025, versus $284.5 million for Q2 2025 and $232.1 million for Q1 2025.